Home > Executive Order

AI Summary: This is a policy document - specifically an Executive Order issued by the President regarding prescription drug pricing. This regulation aims to address what the administration views as unfair drug pricing practices that force American patients to pay significantly higher prices for prescription drugs compared to other developed nations. The order directs multiple federal agencies to take specific actions to reduce drug prices, including communicating "most-favored-nation price targets" to pharmaceutical manufacturers within 30 days. If pharmaceutical manufacturers do not make significant progress in lowering prices, the Secretary of Health and Human Services must propose rulemaking to impose most-favored-nation pricing, consider drug importation from countries with lower prices, and potentially support antitrust enforcement actions. The executive order empowers various agencies like the Department of Commerce, Food and Drug Administration, and Federal Trade Commission to review and potentially take actions such as modifying drug approvals, investigating anti-competitive practices, and reviewing pharmaceutical export regulations. The ultimate goal is to ensure Americans pay prices comparable to those in other developed countries, addressing what the order characterizes as a system where Americans subsidize global pharmaceutical research and development through excessive drug prices.